BTI
LABT

Blue Trust Inc’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

Blue Trust Inc’s Portfolio LABT Stock Details LABT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35 Buy
+11
New +$189 ﹤0.01% 2429

Other funds holding LABT

MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Blue Trust Inc's LABT Position: Q2 2026 in Review

Blue Trust Inc opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q2 2026: 11 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #2429 among its holdings.

6 funds tracked by Wall St. Rank hold LABT as of Q2 2026.

  • Blue Trust Inc held 11 shares of Lakewood-Amedex Biotherapeutics worth $35 as of Q2 2026.
  • Lakewood-Amedex Biotherapeutics was a new Blue Trust Inc position in Q2 2026.
  • Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2429 holding.
  • 6 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.